Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lawmakers Press OMB To Release Lab-Developed Test Draft Guidance

This article was originally published in The Gray Sheet

Executive Summary

In a letter to Office of Management and Budget director Sylvia Mathews, nine Democratic representatives urged the release of a draft guidance establishing an FDA oversight structure for laboratory-developed tests. FDA said more than a year ago that the documents were under administrative review.

You may also be interested in...



Senators Push OMB For Lab-Developed Test Guidance, Academic Labs Resist

Several Democratic Senators want the Office of Management and Budget to release the FDA draft guidance on lab-developed tests that has been stuck at OMB for years. Academic clinical labs send their own letter to the budget office, pleading that the guidance not be released.

Senators Push OMB For Lab-Developed Test Guidance, Academic Labs Resist

Several Democratic Senators want the Office of Management and Budget to release the FDA draft guidance on lab-developed tests that has been stuck at OMB for years. Academic clinical labs send their own letter to the budget office, pleading that the guidance not be released.

FDA Approves First Next-Generation DNA Sequencing Platforms

Illumina’s MiSeqDx instrument and MiSeqDx Universal Kit, granted de novo approval, allow clinicians to “develop and validate sequencing of any part of a patient’s genome,” FDA says.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032330

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel